AstraZeneca

AstraZeneca appoints Joris Silon as Head of Investor Relations

Saphnelo self-administration TULIP-SC trial demonstrates statistically significant and clinically meaningful reduction in systemic lupus erythematosus disease activity

Saphnelo enabled oral corticosteroid reduction while maintaining clinical response in a key secondary endpoint. Patients achieved remission with Saphnelo as demonstrated in an exploratory endpoint.

Director/PDMR Shareholding

Enhertu granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

Tenth Breakthrough Therapy Designation for AstraZeneca and Daiichi Sankyo’s Enhertu with the latest based on DESTINY-Breast05 Phase III trial results.

Update on LATIFY Phase III trial of ceralasertib plus Imfinzi in previously treated advanced non-small cell lung cancer

Director/PDMR Shareholding

Saphnelo approved in the EU for subcutaneous self-administration as a new pre-filled pen for systemic lupus erythematosus

Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion.

Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

Based on DESTINY-Breast09 Phase III trial results that showed AstraZeneca and Daiichi Sankyo’s Enhertu in combination with pertuzumab reduced the risk of disease progression or death by 44% vs. THP with a median progression-free survival of more than three years.

Subcutaneous Saphnelo approved in EU

Enhertu approved in US for 1L HER2+ metastatic BC

Holding(s) in Company

AstraZeneca advances haematology and cell therapy ambition with largest-ever presence at ASH

Investigational T-cell engager, surovatamig, and CAR T-cell therapy, AZD0120, will show potential with initial data across multiple blood cancers. New results will showcase benefit of Calquence in patients with mantle cell lymphoma and chronic lymphocytic leukaemia. New data will further support clinical benefits of Ultomiris in paroxysmal nocturnal haemoglobinuria and its potential to improve outcomes for paediatric patients with haematopoietic stem cell transplant-associated thrombotic microangiopathy.